Solara Active Pharma Reports Rs 101 Million Q2 Loss Despite Rs 3.14 Billion Revenue

Operational Challenges Weigh On Quarterly Results  

Solara Active Pharma Sciences Ltd has announced its financial results for the second quarter of FY2025–26, reporting a consolidated revenue of Rs 3.14 billion and a net loss of Rs 101 million. The company, known for its active pharmaceutical ingredient (API) manufacturing, cited pricing pressure and lower export volumes as key factors behind the loss.

While revenue remained steady, profitability was affected by higher input costs and delayed regulatory approvals in certain geographies. The company is actively working on cost optimization and portfolio diversification to mitigate these challenges.

Management remains focused on strengthening its compliance framework, expanding its product pipeline, and enhancing operational efficiency. Strategic investments in backward integration and capacity expansion are expected to support long-term growth.

Major Takeaways  

• Q2 FY2025–26 consolidated revenue: Rs 3.14 billion  
• Net loss for the quarter: Rs 101 million  
• Margin pressure from input costs and regulatory delays  
• Export volumes impacted by subdued demand  
• Focus on cost control and portfolio diversification  

Sources: BSE India, Business Standard, Moneycontrol, Solara Active Pharma Investor Filings